Novo Nordisk’s Sogroya is now approved for children aged 2.5 or older with idiopathic short stature, small for gestational age, and Noonan Syndrome.

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya (R) (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...

Battles are emerging between tech companies and governments that are trying to limit the harm to children and adolescents ...

The FDA has approved three new pediatric indications for somapacitan-beco, a once-weekly, long-acting growth hormone injection, according to a press release issued by Novo Nordisk.Somapacitan-beco ...

FDA expands Sogroya approval for pediatric patients with Noonan syndrome, idiopathic short stature, and those born small for gestational age.

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for ...

Here are the common bedtime habits that may harm your child’s sleep, growth and brain development and know expert tips to ...

Novo Nordisk A/S (NYSE:NVO) is one of the best cheap stocks under $50 to buy right now. Novo Nordisk A/S (NYSE:NVO) announced ...

Navepegritide is indicated for those ages 2 and older with open epiphyses ...

She revolutionized women’s sprinting with her speed and flamboyant fashion sense, and was a three-time gold medalist at the ...

News and commentary from the endocrinology world ...

A Pontiac couple, as well as their adult son, appeared in court on Friday for allegedly starving and torturing their young ...